Nanjing NingQi Medicine Science and Technology
CompanyChinaROR
Nanjing NingQi Medicine Science and Technology develops 4 assets, the furthest approved (semaglutide in cardiovascular disease). Mostly small molecule and peptide acting on inflammation, Insulin/IGF-1 signalling and lipid and ceramide metabolism; based in China.
- Assets
- 4
- Furthest
- Approved
- Trials
- 19
- Signals
- 4
Pipeline
4GLP-1 receptor agonist
ApprovedPeptideInsulin/IGF-1 signallingLipid and ceramide metabolismcardiovascular diseasechronic kidney disease
mTOR inhibitor delivered perivascularly via a collagen implant to improve arteriovenous fistula maturation.
Phase 3Small moleculeAutophagymTOR signallingagedaging
Flavonoid compound with anti-inflammatory, antioxidant, and antiviral activities
Phase 2Small moleculeOxidative stress and ROS signallingInflammationinfluenza
1 more asset
Full company profiles: pipeline, trials, funding and people.
See Pro- Evidence behind the mechanisms10
- Trials19
- Signals12
- Similar companies6
Updated 7 Oct 2026 · 156 sources